Key Takeaways ABBV's oncology sales made up over 12% of total revenues in Q1 2025, with five therapies now on the market. Emrelis, ABBV's first internally developed lung cancer drug, is expected to contribute starting Q3 2025. New late-stage candidates like etentamig and Temab-A highlight ABBV's advancing cancer drug pipeline.AbbVie (ABBV) has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the company has also been expanding its offerings into sol ...

Enrollment is now underway across multiple clinical sites, in partnership with Syneos HealthVANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the first patient has been dosed in the Company’s clinical trial evaluating the efficacy of leronlimab in patients with relapsed/refractory microsatellite stable c ...

Key Takeaways GH raised 2025 revenue guidance to $880-$890M, driven by rising test volume and ASPs. TEM posted 75% revenue growth and a $200M foundation model deal but remains unprofitable. GH expects breakeven for non-screening ops by Q4 2025, with lower cash burn excluding Shield.Tempus AI (TEM) and Guardant Health (GH) are two dominant players in the field of AI-powered precision oncology. Tempus, newly public and rapidly scaling, reported a 75% year-over-year revenue growth in the first quarter of 202 ...

Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated process to explore strategic alternatives to maximize shareholder valueCAMBRIDGE, Mass., June 23, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported updated results from Part B of the DeFianCe study ( ...

Key Takeaways Pfizer's oncology sales make up 25% of total revenues, boosted by its 2023 Seagen acquisition. Bristol Myers expands its oncology pipeline with Mirati and RayzeBio acquisitions and new drug approvals. PFE shows better stock performance and a 7.2% dividend yield, edging out BMY's 5.29% amid valuation parity.Pharma/biotech giants Pfizer (PFE) and Bristol Myers (BMY) boast of a dominant position in the lucrative oncology space.Oncology or cancer is one of the most sought-after areas in the phar ...

Carrying a Zacks Rank #3 (Hold) at present, the laboratory service provider is concentrating more on areas that represent major growth opportunities and are expected to grow significantly faster than other therapeutic areas. It maintains a solid pipeline of potential acquisitions that fit its financial strategy and will enhance its organic growth. Additionally, the success of the LaunchPad initiative and a solid financial footing are highly encouraging for the company. Based in Burlington, NC, Labcorp offer ...

The cancer diagnostic firm Caris Life Sciences is set to list on the NASDAQ today. The company actually priced its IPO at $21 a share. That was above its expected range.Joining us right now is David Dean Halbert. He is Caris Life Scienc's founder, chairman, and CEO. And David, welcome.Thank you, Becky. Uh let's talk a little bit about what your company does because it's really interesting AI using life sciences to try and go after identify tumors and and find unique ways to deal with each of those cancer tu ...

Virtual investor event planned for July 8 at 2:00pm EDT ROCKVILLE, Md., June 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that it will host a webinar to recap new givastomig data being presented at ESMO GI 2025, with a key opinion leader (KOL), on Tuesday, July 8, 2025 at 2:00pm EDT. To register, click here. Event to follow presentation of ne ...

I-Mab (IMAB) Conference June 17, 2025 10:00 AM ET Speaker0 Great. We'll get started now. I'd like to welcome everybody to HCW's at home series. Today, we're hosting EyeMed Biopharma. My name is Andres Malvinato. I'm a senior health care analyst here at HC Wainwright, and it's my pleasure to host, you today. And it's my pleasure to introduce, IMAD Biopharma's chief executive officer, Sean Fu, and IMAD's chief medical officer, Philip Dennis. So the crux of our fireside chat will be to give you an overview of ...

Core Insights - Moderna is focusing on its oncology pipeline as a key area of interest for investors moving forward [3][4]. Company Overview - The conference call is part of Barclays' 8th annual speaking science conference series, aimed at discussing scientific concepts, clinical program progress, and company strategy [1][2]. Oncology Pipeline - Rose Loughlin, EVP of Research, is presenting a comprehensive slide deck regarding Moderna's oncology pipeline, indicating its importance in the company's future development [3][5]. - The oncology space is highlighted as a significant focus for Moderna, with expectations of substantial investor interest [3].